Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of ethanol and onabotulinumtoxinA is a therapeutic approach used primarily for treating spasticity, particularly in children with cerebral palsy. This combination allows physicians to target more muscles than using onabotulinumtoxinA alone[2]. ## Mechanism of Action The combination works through complementary mechanisms: - **OnabotulinumtoxinA** (Botox) is a botulinum toxin A product that works on the nervous system to relax muscles by blocking acetylcholine release[1][4]. It temporarily prevents muscle contractions by inhibiting the release of the neurotransmitter acetylcholine at the neuromuscular junction. - **Ethanol neurolysis** works by chemically destroying or damaging nerve tissue to reduce muscle spasticity[2][3]. This provides a longer-lasting effect compared to onabotulinumtoxinA alone. When used together, these agents can provide more comprehensive treatment for spasticity, allowing physicians to target more muscles than would be possible with onabotulinumtoxinA alone[2]. ## Clinical Evidence A prospective cohort study found that combined onabotulinumtoxinA and ethanol injections had a slightly greater magnitude of improvement (3.78/5) compared to onabotulinumtoxinA injections alone (3.44/5) when controlled for weight[2]. The study included 167 children with cerebral palsy, with 55 receiving the combination therapy and 112 receiving onabotulinumtoxinA only. ## Administration The combination is administered through injection using both ultrasound guidance and electrical stimulation to ensure precise targeting of affected muscles[2]. This technique helps minimize adverse effects and maximize therapeutic benefits. ## Safety Profile The combination therapy appears to be relatively safe. In the study mentioned, only two patients in the combined therapy group reported mild, self-limiting adverse effects, compared to one patient in the onabotulinumtoxinA-only group[2]. This suggests that adding ethanol does not significantly increase the risk of adverse effects. ## Indications The primary indication for this combination is: - Spasticity in children with cerebral palsy[2][8] It may also be considered for other conditions where focal spasticity is present[3]. ## Potential Side Effects Side effects of the combination may include: - Pain at injection site - Flu-like symptoms - Mild, self-limiting adverse effects[2][3] Additionally, ethanol neurolysis carries risks of: - Tissue or vascular injury - Muscle necrosis and fibrosis - Dysesthesias (when injected near mixed motor and sensory nerves) - Permanent weakness due to nerve damage[3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ethanol and OnabotulinumtoxinA Combination.